Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Maribavir in Healthy Japanese and Caucasian Subjects
NCT04497883Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maribavir in cytomegalovirus infection (CMV) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration at Day 1 and 1 more. Started Aug 2020; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04497883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497883.